# Molecularly Tailored Artesunate Nanomedicine with Well-Balanced Nanoassembly and Anticancer Performance

**Authors:** Haonan Wu, Xuan Zhang, Xiaomei Shu, Hongyuan Zhang, Wenhu Zhou, Shenwu Zhang, Cong Luo

PMC · DOI: 10.3390/pharmaceutics18020240 · 2026-02-14

## TL;DR

Researchers developed a new nanomedicine using artesunate that improves cancer treatment by balancing drug delivery and effectiveness.

## Contribution

A novel unsaturated aliphatic chain-driven strategy enhances artesunate's antitumor activity while maintaining nanoassembly stability.

## Key findings

- Unsaturated aliphatic chain conjugates (ART-LA) retain antitumor activity and self-assemble effectively.
- ART-LA-based nanomedicine shows improved pharmacokinetics and tumor-specific distribution in mice.
- The strategy enhances artesunate's clinical potential by reducing toxicity and improving tumor selectivity.

## Abstract

Background: Artesunate (ART), a natural product derivative of artemisinin, exhibits striking antitumor activity. However, the clinical translation of ART is limited by rapid clearance, poor tumor selectivity, and severe off-target toxicity. To address these limitations, we developed an unsaturated aliphatic chain-driven nanoassembly strategy to optimize the therapeutic performance of ART. Methods: We designed and synthesized two ART derivatives by conjugating saturated aliphatic chains (ART-SAs) or unsaturated aliphatic chains (ART-LAs) to ART, which subsequently self-assembled into carrier-free nanoassemblies (NAs). These NAs were characterized for their self-assembly capacity and colloidal stability. Biological evaluations included studies on cellular uptake efficiency, in vivo pharmacokinetics, and antitumor efficacy in a tumor-bearing mouse model. Results: The saturated aliphatic chain is found to drive nanoassembly of ART-SA but significantly shields the antitumor activity of ART. Interestingly, the conjugate of an unsaturated aliphatic chain to ART (ART-LA) not only shows outstanding self-assembly capacities but also retains the native antitumor activity of ART. The P-AL NAs with improved pharmacokinetics and tumor-specific biodistribution exert potent antitumor activity and favorable safety. Conclusions: We successfully applied ART for highly effective antitumor therapy by employing an unsaturated aliphatic chain-driven strategy. This study is conducive to promoting the clinical application of ART.

## Linked entities

- **Chemicals:** artesunate (PubChem CID 6917864)
- **Diseases:** cancer (MONDO:0004992)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Art2b (ADP-ribosyltransferase 2b) [NCBI Gene 11872] {aka ART2.2, ARTC2, Art, Ly92b, Rt-6, Rt6}
- **Diseases:** injury to (MESH:D014947), Cancer (MESH:D009369), leukemia (MESH:D007938), Cytotoxicity (MESH:D064420), weight loss (MESH:D015431)
- **Chemicals:** DCFH-DA (MESH:C029569), water (MESH:D014867), LA (MESH:D007811), ethanol (MESH:D000431), ART (MESH:D000077332), aldehyde (MESH:D000447), artemisinin (MESH:C031327), DTT (MESH:D004229), SDS (MESH:D012967), oxygen (MESH:D010100), formazan (MESH:D005562), NaCl (MESH:D012965), P-AS (MESH:D011478), stearyl alcohol (MESH:C009316), ester (MESH:D004952), acetonitrile (MESH:C032159), LPO (MESH:D008054), F12 (MESH:C007782), DCM (MESH:D008752), nitrogen (MESH:D009584), lipid (MESH:D008055), linolenic alcohol (MESH:C037936), GSH (MESH:D005978), CO2 (MESH:D002245), DMSO (MESH:D004121), ROS (MESH:D017382), EDCI (MESH:D005022), PBS (MESH:D007854), N-acetyl-L-cysteine (MESH:D000111), hydrogen (MESH:D006859), heparin sodium (MESH:D006493), linoleyl alcohol (MESH:C059691), SA (MESH:D000077145), Na (MESH:D012964), disulfide (MESH:D004220), 1H (-), 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (MESH:C000613388), H&amp;E (MESH:D006371), fatty acid (MESH:D005227), MDA (MESH:D008315), Urea (MESH:D014508), MTT (MESH:C070243)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** BALB/C — Mus musculus (Mouse), Transformed cell line (CVCL_4350), 3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), /C — Mus musculus (Mouse), Finite cell line (CVCL_S361), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944037/full.md

---
Source: https://tomesphere.com/paper/PMC12944037